by: Ivana
Latar Belakang
Nama : Biontech SE
Ticker : NASDAQ: BNTX
Harga: 277.44 $ (per 29 September 2021)
BioNTech SE, adalah sebuah perusahaan yang mengembangkan dan mengkomersialisasikan terapi dan penyembuhan untuk kanker dan penyakit menular lainnya. Sejak 2008 beberapa produk yang sedang dan telah dikembangkan adalah pengobatan kanker seperti kanker melanoma, prostat, payudara, untuk menyembuhkan HPV+ kanker kepala dan leher, ovarium dengan metode imunoterapi. Imunoterapi adalah salah satu cara untuk menyembuhkan kanker dengan menggunakan kekebalan tubuh kita sendiri. BioNtech sendiri telah mencapai pengujian tahap II dalam pengajuan metodenya tersebut. Saat ini, yang membuat Perusahaan ini dikenal, adalah karena telah berhasil mengembangkan vaksin COVID-19 yang telah di akui oleh FDA sejak 23 Aug 2021 dan telah disebarluaskan ke seluruh dunia dengan berkolaborasi dengan Pfizer Inc. Perusahaan-perusahaan lain yang telah berkolaborasi dengan BioNtech SE adalah Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; dan Regeneron Pharmaceuticals, Inc.
Tinjauan Industri
Sejak IPO 10 Sep 2019, dengan harga penawaran 15 $ – 16 $, saham BioNtech saat ini yang berada di harga 277.44 $ telah naik sebanyak 18.5 kali lipat.
Untuk masyarakat Amerika Serikat sendiri, mereka telah menerima vaksin Pfizer sebanyak hampir dua kali lipat dibanding pesaingnya Moderna, Inc. yang bisa dilihat dari grafik dibawah ini.
Ikhtisar Keuangan
Biontech telah melewati semua kriteria daftar checklist kami, kecuali Cash Flow Ratio dari net income. Hal ini dikarenakan peningkatan investasi perusahaan yang tinggi sebesar 480 persen selama satu tahun yang memperlihatkan kemungkinan adanya pertumbuhan investasi jangka panjang. Hal ini bisa terus dimonitor sehingga kita mengetahui apakah investasi jangka Panjang itu benar-benar berdampak terhadap hasil atau revenue yang diperoleh perusahaan.
Ringkasan Investasi
Teknologi Biontech saat ini masih digunakan oleh pasar dunia dikarenakan adanya vaksin covid 19 yang telah menjadi pandemic yang menyebar di seluruh dunia, dan 1-2 tahun kedepan akan adanya vaksin untuk anak2 dan booster untuk vaksin covid 19 yang telah mulai disebarkan di Amerika dimana Presiden Biden sendiri menggunakan vaksin ini.
Untuk jangka panjangnya, perusahaan Biontech terus melakukan penelitian dan pengembangan untuk vaksin flu, pneumonia, perawatan dan pengobatan penyakit kanker dan penyakit-penyakit lainnya.
Kompetisi Pasar
Di pasaran, Biontech bukan satu-satunya yang mengembangkan teknologi vaksin. Perusahaan seperti Moderna, Johnson and Johnson, dan perusahaan China seperti Sinovac dan Sinopharm juga membuat vaksin untuk covid 19 (hanya saja yang diakui oleh FDA saat ini baru Biontech) dimana yang lainnya adalah emergency approval.
| Treatment Name | Company | FDA Approval | data efficacy |
| Pfizer vaccine (Comirnaty) | Biontech & Pfizer | 8/23/2021 Full approval | 95% |
| mRNA1273 | Moderna vaccine | emergency authotization in US, EU and UK | 94.10% |
| NVX Cov2373 | Novavax | phase 3 | 90.40% |
| CoronaVac | Sinovac | emergency use in China | 50.40% |
| Sinopharm | Sinopharm | accepted in UAE and conditional approval in China | 86% |
| Vaxzevria | AstraZeneca | emergency authotization in UK, India and EU | 79% |
| JNJ78436735 | Johnson and Johnson | emergency authorization in US, EU and UK | 66% |
Valuasi
| Methode | Target Price | Potensi cuan | Period |
| Discounted Cash Flow | NA | NA | 1-3 years |
| Residual Earning | 391 | 41% | 1-3 years |
| Technical Analysis | NA | NA | 3-6 months |
| Tipranks analyst average (reference) | 373 | 36% | NA |
| Artifical Intelligence Kosho AI (reference) | NA | 3.3% | 3 months |
Sumber:
https://finance.yahoo.com/quote/BNTX/profile?p=BNTX
https://www.renaissancecapital.com/Profile/BNTX/BioNTech/IPO
https://www.usatoday.com/in-depth/graphics/2021/01/14/covid-vaccine-distribution-by-state-how-many-covid-vaccines-have-been-given-in-us-how-many-people/6599531002/
*** Ini adalah pendapat penulis, silakan berkonsultasi dengan penasihat keuangan Anda dan lakukan uji tuntas Anda sendiri sebelum berinvestasi. Pundireceh tidak bertanggung jawab atas segala kewajiban yang terkait dengan risiko investasi.
# BioNTech (NASDAQ:BNTX) sesuai dengan persyaratan syariah. Kondisi bisnis, produk, dan utangnya memenuhi kriteria Hukum Islam dan halal untuk diinvestasikan, berdasarkan analisis aplikasi Zoya (https://zoya.finance/).
===================================================================
by: Ivana
Background
Name : Biontech SE
Ticker : NASDAQ: BNTX
Price: 277.44 $ (as of September 29, 2021)
BioNTech SE, is a company that develops and commercializes therapies and cures for cancer and other infectious diseases. Since 2008 several products that are being and have been developed are cancer treatments such as melanoma, prostate, breast cancer, to cure HPV+ head and neck cancer, ovarian with immunotherapy methods. Immunotherapy is one way to cure cancer by using our own immunity. BioNtech itself has reached phase II testing in the submission of the method. Currently, what makes this Company known, is because it has successfully developed a COVID-19 vaccine that has been approved by the FDA since 23 Aug 2021 and has been distributed worldwide in collaboration with Pfizer Inc. Other companies that have collaborated with BioNtech SE are Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc.
Industry Overview
Since the IPO 10 Sep 2019, with an offering price of 15$ – 16$, BioNtech’s current stock at 277.44$ has gone up 18.5 times.
For the United States alone, they have received nearly twice as much Pfizer’s vaccine as its competitor Moderna, Inc. which can be seen from the graph below.
Financial Overview
Biontech has passed all of our checklist criteria, except Cash Flow Ratio from net income. This is due to the company’s high investment increase of 480 percent during one year which shows the possibility of long-term investment growth. This can be continuously monitored so that we know whether the long-term investment really has an impact on the results or revenue obtained by the company.
Investment Summary
Biontech technology is currently still used by the world market due to the covid 19 vaccine which has become a pandemic that has spread throughout the world, and in the next 1-2 years there will be a vaccine for children and a booster for the covid 19 vaccine which has begun to be spread in America where President Biden own use of this vaccine.
For the long term, the Biontech company continues to carry out research and development for flu vaccines, pneumonia, treatment and treatment of cancer and other diseases.
Market positioning
In the market, Biontech is not the only one developing vaccine technology. Companies such as Moderna, Johnson and Johnson, and Chinese companies such as Sinovac and Sinopharm are also making vaccines for COVID-19 (only Biontech is currently only recognized by the FDA).
| Treatment Name | Company | FDA Approval | data efficacy |
| Pfizer vaccine (Comirnaty) | Biontech & Pfizer | 8/23/2021 Full approval | 95% |
| mRNA1273 | Moderna vaccine | emergency authotization in US, EU and UK | 94.10% |
| NVX Cov2373 | Novavax | phase 3 | 90.40% |
| CoronaVac | Sinovac | emergency use in China | 50.40% |
| Sinopharm | Sinopharm | accepted in UAE and conditional approval in China | 86% |
| Vaxzevria | AstraZeneca | emergency authotization in UK, India and EU | 79% |
| JNJ78436735 | Johnson and Johnson | emergency authorization in US, EU and UK | 66% |
Valuation
| Methode | Target Price | Potensi cuan | Period |
| Discounted Cash Flow | NA | NA | 1-3 years |
| Residual Earning | 391 | 41% | 1-3 years |
| Technical Analysis | NA | NA | 3-6 months |
| Tipranks analyst average (reference) | 373 | 36% | NA |
| Artifical Intelligence Kosho AI (reference) | NA | 3.3% | 3 months |
Source
https://finance.yahoo.com/quote/BNTX/profile?p=BNTX
https://www.renaissancecapital.com/Profile/BNTX/BioNTech/IPO
https://www.usatoday.com/in-depth/graphics/2021/01/14/covid-vaccine-distribution-by-state-how-many-covid-vaccines-have-been-given-in-us-how-many-people/6599531002/
*** This is the opinion of the author, please consult your financial advisor and do your own due diligence before investing. Pundireceh is not responsible for any obligations related to investment risk.
#BioNTech (NASDAQ:BNTX) complies with sharia requirements. The business conditions, products and debts meet the criteria of Islamic Law and are halal to invest in, based on the analysis of the Zoya application (https://zoya.finance/).